立他司特:黏附因子抑制剂类干眼症新药  

Lifitegrast:A novel inhibitor of integrin for dry eye disease

作　　者：郑飞[1] 王艳梅[2] 张谦[1] 巩颖[1] 顾媛媛[1] 华国栋[1] 

机构地区：[1]北京中医药大学东方医院药学部,北京100078 [2]北京中医药大学东直门医院药学部,北京100700

出　　处：《药物评价研究》2017年第6期880-884,共5页Drug Evaluation Research

摘　　要：立他司特(Lifitegrast)是一种新的细胞间黏附因子的抑制剂,可以通过阻断细胞间黏附分子-1和整合素蛋白淋巴细胞功能相关抗原-1之间的结合起效。2016年7月,美国食品药品管理局(FDA)正式批准了5%立他司特滴眼剂(商品名XiidraTM)的申请。该药的临床试验主要包括针对干眼症患者的1个为期12周的II期临床试验和3个为期12周的III期临床试验,研究结果充分证明了该药的有效性和安全性。立他司特是FDA批准的第一个可以改善和治疗干眼症症状的新药,其他类似药物只有环孢素,在不久的将来其临床应用会更加广泛。Lifitegrast is a novel inhibitor of integrin,which can take effect by blocking the binding of intercellular adhesion molecule 1 and integrin lymphocyte function associated antigen 1.In July 2016,the U.S.Food and Drug Administration （FDA） officially approved the application of lifitegrast ophthalmic solution 5% （commodity name XiidraTM）.Clinical trials of the drug include a 12-week phase II clinical trial and three 12-week phase III clinical trials for dry eye disease patients.The results of clinical trials have demonstrated the efficacy and safety of the drug.Lifitegrast is the first FDA approved drug to improve and treat dry eye symptoms,and other similar drug is only cyclosporine.It is believed that in the near future clinical application of lifitegrast will be more extensive.

关 键 词：立他司特 滴眼剂 黏附因子抑制剂 干眼症 

分 类 号：R988.1[医药卫生—药品]